Cargando…

Unlocking the Therapeutic Potential of Glucagon-Like Peptide-1 Analogue and Fibroblast Growth Factor 21 Combination for the Pathogenesis of Atherosclerosis in Type 2 Diabetes

Detalles Bibliográficos
Autor principal:	Son, Jang Won
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Korean Endocrine Society 2021
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7937850/ https://www.ncbi.nlm.nih.gov/pubmed/33677927 http://dx.doi.org/10.3803/EnM.2021.109

Ejemplares similares

Effects of Glucagon-Like Peptide-1 Analogue and Fibroblast Growth Factor 21 Combination on the Atherosclerosis-Related Process in a Type 2 Diabetes Mouse Model
por: Kim, Jin Hee, et al.
Publicado: (2021)

Glucagon-like peptide-1 analogues: An overview
por: Gupta, Vishal
Publicado: (2013)

Glucagon-like Peptide-1 Receptor Analogues for the Treatment of Obesity
por: Williams, David M, et al.
Publicado: (2022)

Effects of Glucagon-Like-Peptide-1 Analogue Treatment in Genetic Obesity
por: Welling, Mila Sofie, et al.
Publicado: (2021)

Investigating the Glucagon Receptor and Glucagon-Like Peptide 1 Receptor Activity of Oxyntomodulin-Like Analogues in Male Wistar Rats
por: Price, Samantha L., et al.
Publicado: (2015)

The therapeutic potential of a venomous lizard: the use of glucagon-like peptide-1 analogues in the critically ill
por: Deane, Adam M, et al.
Publicado: (2010)

Glucagon-Like Peptide 1 Receptor Agonists, Carotid Atherosclerosis, and Cardiovascular Outcomes
por: Marquis-Gravel, Guillaume, et al.
Publicado: (2021)

Liver-derived fibroblast growth factor 21 mediates effects of glucagon-like peptide-1 in attenuating hepatic glucose output
por: Liu, Junling, et al.
Publicado: (2019)

Glucagon-like peptide-1 analogues - an efficient therapeutic option for the severe insulin resistance of lipodystrophic syndromes: two case reports
por: Oliveira, Joana, et al.
Publicado: (2017)

Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis
por: Shyangdan, Deepson S, et al.
Publicado: (2010)

Glucagon-Like Peptide-2 Analogue ZP1849 Augments Colonic Anastomotic Wound Healing
por: Kjaer, Marie, et al.
Publicado: (2020)

Can glucagon-like peptide-1 (GLP-1) analogues make neuroprotection a reality?
por: Basalay, Maryna V., et al.
Publicado: (2020)

Effects of glucagon‐like peptide‐1 analogue treatment in genetic obesity: A case series
por: Welling, Mila S., et al.
Publicado: (2021)

Role of Fibroblast Growth Factor 21 in Biology of Glucagon
por: Berglund, Eric D., et al.
Publicado: (2013)

The Glucagon-Like Peptide 1 Analogue, Exendin-4, Attenuates the Rewarding Properties of Psychostimulant Drugs in Mice
por: Egecioglu, Emil, et al.
Publicado: (2013)

Glucagon-like peptide-2 analogues for Crohn’s disease patients with short bowel syndrome and intestinal failure
por: Pizzoferrato, Marco, et al.
Publicado: (2022)

Computational Peptide Design Cotargeting Glucagon and Glucagon-like Peptide-1 Receptors
por: Vishnoi, Shubham, et al.
Publicado: (2023)

Fibroblast Growth Factor 21 Mediates Specific Glucagon Actions
por: Habegger, Kirk M., et al.
Publicado: (2013)

Stability of glucagon-like peptide 1 and glucagon in human plasma
por: Wewer Albrechtsen, Nicolai J, et al.
Publicado: (2015)

Glucagon and other proglucagon-derived peptides in the pathogenesis of obesity
por: Holst, Jens Juul
Publicado: (2022)

Glucagon-like peptide-1 and glucagon-like peptide-2 regulation during human liver regeneration
por: Ammann, Markus, et al.
Publicado: (2023)

Effect of the Glucagon‐like Peptide‐1 Analogue Exenatide Extended Release in Cats with Newly Diagnosed Diabetes Mellitus
por: Riederer, A., et al.
Publicado: (2016)

Glucagon-like peptide-1 analogue exendin-4 modulates serotonin transporter expression in intestinal epithelial cells
por: Cui, Xiufang, et al.
Publicado: (2020)

Potential Roles of Glucagon-Like Peptide-1 and Its Analogues in Dementia Targeting Impaired Insulin Secretion and Neurodegeneration
por: Mehan, Sidharth, et al.
Publicado: (2022)

Pharmacokinetics of Glepaglutide, A Long-Acting Glucagon-Like Peptide-2 Analogue: A Study in Healthy Subjects
por: Agersnap, Mikkel Askjær, et al.
Publicado: (2022)

THU294 Glucagon Like Peptide-1 Analogue Therapy In Obese Patients With Cystic Fibrosis Related Diabetes
por: Reddy Ankireddypalli, Anvitha, et al.
Publicado: (2023)

Glucagon-Like Peptide-1 and Diabetes
por: Monami, Matteo
Publicado: (2011)

Crystal Structure of Glucagon-like Peptide-1 in Complex with the Extracellular Domain of the Glucagon-like Peptide-1 Receptor
por: Underwood, Christina Rye, et al.
Publicado: (2010)

Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
por: Lee, Seungah, et al.
Publicado: (2017)

Glucagon-like peptide 1 and Glucagon-like peptide 2 in relation to osteoporosis in non-diabetic postmenopausal women
por: Montes Castillo, María Cristina, et al.
Publicado: (2019)

Regulation of intestinal lipid and lipoprotein metabolism by the proglucagon-derived peptides glucagon like peptide 1 and glucagon like peptide 2
por: Mulvihill, Erin E.
Publicado: (2018)

Glucagon‐like peptide‐1 receptor agonists and their effects on weight reduction
por: Shin, Shyi‐Jang
Publicado: (2012)

Glycosaminoglycan Conjugation for Improving the Duration of Therapeutic Action of Glucagon-Like Peptide-1
por: Ichikawa, Megumi, et al.
Publicado: (2018)

Glucagon-like peptide-1 analogue, liraglutide, in experimental cerebral malaria: implications for the role of oxidative stress in cerebral malaria
por: DellaValle, Brian, et al.
Publicado: (2016)

Exendin-4, a glucagon-like peptide-1 analogue accelerates healing of chronic gastric ulcer in diabetic rats
por: Chen, Yen-Cheng, et al.
Publicado: (2017)

Glycemic variability in newly diagnosed diabetic cats treated with the glucagon‐like peptide‐1 analogue exenatide extended release
por: Krämer, Anna L., et al.
Publicado: (2020)

The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission
por: Chuong, Vicky, et al.
Publicado: (2023)

Therapeutic Effect of Exendin-4, a Long-Acting Analogue of Glucagon-Like Peptide-1 Receptor Agonist, on Nerve Regeneration after the Crush Nerve Injury
por: Yamamoto, Koji, et al.
Publicado: (2013)

Glucagon-Like Peptide-1 Gene Therapy
por: Rowzee, Anne M., et al.
Publicado: (2011)

Glucagon-Like Peptide-1 and Diabetes 2012
por: Monami, Matteo, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_1bi2lkejqfn9pfnlod464i6n8g